Comment
. 2011 Jun; 103(12):910-3.
doi: 10.1093/jnci/djr195.

Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy

Nicole M Kuderer  Gary H Lyman  
  • PMID: 21670422
  •     39 References
  •     12 citations

No abstract available

Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Gary H Lyman, Jessica Malone Kleiner.
Cancer Treat Res, 2010 Nov 06; 157. PMID: 21052955
Review.
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
Scott D Ramsey, Zhimei Liu, +5 authors, Gary H Lyman.
Value Health, 2008 Aug 05; 12(2). PMID: 18673353
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
M S Aapro, J Bohlius, +10 authors, European Organisation for Research and Treatment of Cancer.
Eur J Cancer, 2010 Nov 26; 47(1). PMID: 21095116
Highly Cited. Systematic Review.
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
Alison G Freifeld, Eric J Bow, +8 authors, Infectious Diseases Society of Americaa.
Clin Infect Dis, 2011 Jan 06; 52(4). PMID: 21205990
Highly Cited.
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.
Gary H Lyman, Nicole M Kuderer, +4 authors, David C Dale.
Cancer, 2011 Apr 22; 117(9). PMID: 21509769    Free PMC article.
Individualized guidelines: the potential for increasing quality and reducing costs.
David M Eddy, Joshua Adler, +3 authors, Macdonald Morris.
Ann Intern Med, 2011 May 04; 154(9). PMID: 21536939
Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.
Suja S Rajan, Gary H Lyman, William R Carpenter, Sally C Stearns.
Breast Cancer Res Treat, 2010 Oct 27; 127(2). PMID: 20976544
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
Arnold L Potosky, Jennifer L Malin, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670423    Free PMC article.
Risk of mortality in patients with cancer who experience febrile neutropenia.
Gary H Lyman, Shannon L Michels, +3 authors, Jingbo Yu.
Cancer, 2010 Aug 18; 116(23). PMID: 20715160
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
Gary H Lyman, David C Dale, +4 authors, Jeffrey Crawford.
J Clin Oncol, 2010 Apr 14; 28(17). PMID: 20385991
Systematic Review.
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
J Klastersky, M Paesmans, +8 authors, J Talcott.
J Clin Oncol, 2000 Aug 16; 18(16). PMID: 10944139
Highly Cited.
Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients.
Michael Darmon, Elie Azoulay, +4 authors, Benoît Schlemmer.
Intensive Care Med, 2002 Nov 26; 28(12). PMID: 12447522
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Gary H Lyman, David J Delgado.
Cancer, 2003 Nov 25; 98(11). PMID: 14635075
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Gary H Lyman, David C Dale, Jeffrey Crawford.
J Clin Oncol, 2003 Dec 16; 21(24). PMID: 14673039
Highly Cited.
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium.
John Z Ayanian, Elizabeth A Chrischilles, +13 authors, Dee W West.
J Clin Oncol, 2004 Jul 31; 22(15). PMID: 15284250
Highly Cited.
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Gary H Lyman, David C Dale, +2 authors, Richard I Fisher.
J Clin Oncol, 2004 Sep 24; 22(21). PMID: 15381684
Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.
J A Talcott, R D Siegel, R Finberg, L Goldman.
J Clin Oncol, 1992 Feb 01; 10(2). PMID: 1732432
Highly Cited.
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
C L Bennett, T J Smith, +6 authors, R J Winn.
J Clin Oncol, 1996 Sep 01; 14(9). PMID: 8823330
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.
L S Elting, E B Rubenstein, K V Rolston, G P Bodey.
Clin Infect Dis, 1997 Aug 01; 25(2). PMID: 9332520
Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome.
J Carratalà, B Rosón, +2 authors, F Gudiol.
Arch Intern Med, 1998 May 07; 158(8). PMID: 9570172
Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.
C Chouaid, L Bassinet, +2 authors, B Housset.
J Clin Oncol, 1998 Aug 15; 16(8). PMID: 9704720
The economics of febrile neutropenia: implications for the use of colony-stimulating factors.
G H Lyman, N Kuderer, J Greene, L Balducci.
Eur J Cancer, 1999 Feb 19; 34(12). PMID: 10023306
Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia.
E González-Barca, A Fernández-Sevilla, +4 authors, F Gudiol.
Eur J Clin Microbiol Infect Dis, 1999 Oct 12; 18(8). PMID: 10517190
Undertreatment of obese women receiving breast cancer chemotherapy.
Jennifer J Griggs, Melony E S Sorbero, Gary H Lyman.
Arch Intern Med, 2005 Jun 16; 165(11). PMID: 15956006
Risk models for predicting chemotherapy-induced neutropenia.
Gary H Lyman, Christopher H Lyman, Olayemi Agboola.
Oncologist, 2005 Jun 22; 10(6). PMID: 15967836
Systematic Review.
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Arti Hurria, Kelly Brogan, +6 authors, Clifford Hudis.
Drugs Aging, 2005 Aug 03; 22(8). PMID: 16060720
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Nicole M Kuderer, David C Dale, +2 authors, Gary H Lyman.
Cancer, 2006 Apr 01; 106(10). PMID: 16575919
Highly Cited.
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Thomas J Smith, James Khatcheressian, +19 authors, Antonio C Wolff.
J Clin Oncol, 2006 May 10; 24(19). PMID: 16682719
Highly Cited.
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
Michael J Hassett, A James O'Malley, +2 authors, Craig C Earle.
J Natl Cancer Inst, 2006 Aug 17; 98(16). PMID: 16912263
Highly Cited.
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Michelle Shayne, Jeffrey Crawford, +3 authors, ANC Study Group.
Breast Cancer Res Treat, 2006 May 18; 100(3). PMID: 16705366
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.
Jennifer J Griggs, Eva Culakova, +6 authors, Gary H Lyman.
J Clin Oncol, 2006 Dec 13; 25(3). PMID: 17159190
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
Jennifer J Griggs, Eva Culakova, +5 authors, Gary H Lyman.
J Clin Oncol, 2007 Jun 20; 25(18). PMID: 17577029
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
Nicole M Kuderer, David C Dale, Jeffrey Crawford, Gary H Lyman.
J Clin Oncol, 2007 Jul 20; 25(21). PMID: 17634496
Highly Cited. Systematic Review.
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
Jeffrey Crawford, David C Dale, +4 authors, Gary H Lyman.
J Natl Compr Canc Netw, 2008 Mar 06; 6(2). PMID: 18319047
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
Adi Eldar-Lissai, Leon E Cosler, Eva Culakova, Gary H Lyman.
Value Health, 2008 Apr 03; 11(2). PMID: 18380630
Myeloid growth factors.
Jeffrey Crawford, James Armitage, +22 authors, National Comprehensive Cancer Network.
J Natl Compr Canc Netw, 2009 Jan 30; 7(1). PMID: 19176207
Impact of chemotherapy dose intensity on cancer patient outcomes.
Gary H Lyman.
J Natl Compr Canc Netw, 2009 Jan 30; 7(1). PMID: 19176210
Review.
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.
David C Dale, Gordon C McCarter, Jeffrey Crawford, Gary H Lyman.
J Natl Compr Canc Netw, 2003 Jul 01; 1(3). PMID: 19761076
Review.
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.
Elizabeth A Chrischilles, Jane F Pendergast, +8 authors, Robert H Fletcher.
J Clin Oncol, 2009 Dec 30; 28(4). PMID: 20038726    Free PMC article.
Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Arnold L Potosky, Jennifer L Malin, +2 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Nov 01; 103(24). PMID: 22036767    Free PMC article.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Review.
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
Gary H Lyman, David C Dale, +4 authors, Jeffrey Crawford.
Cancer Med, 2015 Mar 27; 4(8). PMID: 25810005    Free PMC article.
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Hartmut Link, J Nietsch, +2 authors, Supportive Care Group (ASORS) of the German Cancer Society (DKG).
Support Care Cancer, 2015 Jun 18; 24(1). PMID: 26081593
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
Derek Weycker, Xiaoyan Li, +6 authors, Jacob Garcia.
Support Care Cancer, 2015 Dec 17; 24(6). PMID: 26670915    Free PMC article.
Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Derek Weycker, Xiaoyan Li, +5 authors, Gary H Lyman.
Support Care Cancer, 2016 Oct 14; 25(2). PMID: 27734153
Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.
Sarah Knerr, Elaine Y Hu, Steven B Zeliadt.
EGEMS (Wash DC), 2017 May 02; 5(1). PMID: 28459084    Free PMC article.
A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.
Aasthaa Bansal, Sean D Sullivan, +4 authors, Scott D Ramsey.
J Comp Eff Res, 2017 Jul 08; 6(5). PMID: 28686055    Free PMC article.
Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.
Alper Sevinç, Metin Özkan, +10 authors, Salim Başol Tekin.
Onco Targets Ther, 2018 Feb 07; 11. PMID: 29403286    Free PMC article.
Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy.
Abolfazl Razzaghdoust, Bahram Mofid, Maryam Moghadam.
Support Care Cancer, 2018 May 08; 26(11). PMID: 29736867
Personalized cancer supportive care in COVID-19 era.
G H Lyman, N M Kuderer.
Ann Oncol, 2020 May 15; 31(7). PMID: 32405154    Free PMC article.
Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Derek Weycker, Robin Doroff, +6 authors, Gary H Lyman.
BMC Cancer, 2019 Aug 11; 19(1). PMID: 31399079    Free PMC article.